TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05362253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-Conjunctival Autograft Combined with Amniotic Membrane Transplantation
Description: 1. Disinfection, anaesthesia and excision of recurrent pterygium are the same as conventional autologous conjunctival transplantation.~2. The biological freeze-dried amniotic membrane (Jiangxi Ruiji Biological engineering technology Co., Ltd., Nanchang, China), equivalent in size to the exposed scleral surface, was flat mounted on the exposed scleral area , and the amniotic membrane was fixed on the superficial sclera with 10-0 suture.~3. After amniotic membrane graft was fixed, 2% lidocaine was applied to the superior temporal conjunctiva.~4. Take the conjunctival epithelial graft with the length equivalent to the neck of recurrent pterygium and the width of 1.5mm \~ 2.0mm, and translate it on amniotic membrane surface near corneal limbus. The conjunctival flap was secured with 10-0 suture.~5. Last, tobramycin and dexamethasone eye ointment was applied and bandaged with dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Autologous Conjunctival Transplantation
Description: 1. Routine disinfection and anaesthesia.~2. To bluntly separate and excise pterygium.~3. Remove pterygium tissue on the corneal surface with a round blade.~4. Place a cotton ball slightly infiltrated with diluent Bleomycin A5 Hydrochloride for Injection on the exposed sclera for 1 minute and flushed away later.~5. After anesthesia, take the superior temporal conjunctival epithelium equal to the size of the exposed scleral and translate it to the exposed scleral surface (the limbus side of the graft corresponds to the limbus of the graft bed), and fixed with 10-0 suture.~6. The free conjunctival margin of the conjunctival flap sampling area was sutured intermittently with 10-0 suture.~7. Apply tobramycin dexamethasone eye ointment and wrap the eyes with dressing after operation.
Study: NCT04421014

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Ester drink
Description: The main ingredient of the Ketone Ester drink \[(R)-3-hydroxybutyl (R)-3-hydroxybutyrate)\] is regulated as GRAS (Generally Recognized as Safe) substance by the FDA (https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices\&amp;id=515). The Ketone Ester compound is already being sold in the market as a ketogenic supplement and is especially popular among athletes, such as cyclists (sold by the official website of the company TdeltaS(R) Global (https://www.deltagketones.com/products/g-ketone-performance). The dose and formulation (25 g of KE contained in 59 ml of a drink), daily scheme (3 times daily) and total duration (28 days) are identical to a previous safety human study. The Ketone Ester drink provided by DeltaG will be repackaged by the NIA Pharmacist into new bottles identical to the ones that will be used for the placebo to ensure the blinding of participants and researchers to the drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: isocaloric dextrose drink
Description: The main content of the Placebo will be an aqueous solution containing approximately 35 g of dextrose, a fruity flavor powder and stevia. We will also add Denatonium Benzoate (Bittrex) to match the bitterness of the Ketone Ester drink. The placebo will be prepared and dispensed by the NIA Pharmacist.
Study: NCT06158607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction Clinic-Based PrEP Adherence Intervention for Women with Substance Use Disorders
Description: Provision of PrEP information through 4 counseling sessions, prevention navigation, and nurse practitioner prescribed PrEP in an addiction treatment setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Participants in substance use treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention
Study: NCT06649253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling bone tissue and blood
Description: Extra tube collection of bone and blood will be collected during routine care sampling interventions at the diagnosis, after the first phase of treatment and after relapse, if it occurs.
Study: NCT04365660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-F FTC 146
Description: Radiotracer, 10 mCi at pre- and post- chemotherapy, intravenous administration
Study: NCT04988308

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.
Study: NCT04769518

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Recovery Room Care (ARRC)
Description: High acuity care
Study: NCT04988308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.
Study: NCT04769518

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Advanced Recovery Room Care (ARRC)
Description: High acuity care
Study: NCT05225610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valsalva Manoeuvre
Description: Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: 5 ml saline will be administered.
Study: NCT04988308

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Bermekimab will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT06470217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirilizumab with albumin-bound paclitaxel and cisplatin
Description: tirilizumab administered by intravenous drip (no prophylaxis required) at a fixed dose of 200 mg. each infusion was given for 30 min (not less than 20 min and not more than 60 min) every 3 weeks, and 3 preoperative cycles of albumin-bound paclitaxel 260 mg/m2 and cisplatin 75 mg/m2 on d1, with 1 cycle every 21 days; 3 preoperative Cycles. After neoadjuvant therapy, patients underwent surgery and were stratified according to pathological conditions after surgery; if significant pathological remission (MPR) was achieved, 6 cycles of adjuvant therapy with tirilizumab monotherapy (concurrent radiochemotherapy was available for those with high-risk factors) were performed; if MPR was not achieved, concurrent radiochemotherapy was performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: patients underwent direct surgical treatment, with postoperative radiotherapy or radiochemotherapy depending on the presence or absence of histological or pathological high-risk factors.
Study: NCT04399616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Map
Description: The tool we test in this project (the visual hazard map) aims to enable the practitioner to quickly identify critical areas for systematically implementing relevant safe practices (appropriate for each situation).
Study: NCT04871568

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary central dialysis catheterization
Description: Placement of temporary central dialysis catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary central dialysis catheterization
Description: Placement of temporary central dialysis catheter
Study: NCT04899518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALY688 Ophthalmic Solution
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALY688 Ophthalmic Solution
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALY688 Ophthalmic Solution
Description: Ophthalmic Solution
Study: NCT06029153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization
Description: Middle meningeal artery embolization with coil.
Study: NCT05008432

Intervention type: DIAGNOSTIC_TEST
Intervention: Home sleep apnea testing
Description: Participants will be monitored with a WatchPAT device for home based diagnosis of OSA (for patients hospitalized with HFpEF, the sleep test may be performed in the hospital or at home).
Study: NCT03637062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
Study: NCT06236503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real Stimulation
Description: Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). · Time B:~Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 20 minutes with the anode placed on the international electrode position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Rest Period: 2 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Stimulation
Description: Time A: Behavioral assessment using the Coma Recovery Scale-R (CRS-R). Time B. Transcranial Direct Current Stimulation (tDCS). Frontal stimulation for 5 seconds with the anode placed on the electrode 10-20 position and the cathode on the right supraorbital region. Stimulation will be repeated once a day, 5 days a week, for 4 weeks. · Time C. Behavioral assessment using the Coma recovery Scale-R (CRS-R). Time D. Behavioral assessment using the Coma Recovery Scale-R (CRS-R).
Study: NCT06089135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular Lithotripsy
Description: Intravascular lithotripsy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cutting Balloon
Description: Cutting Balloon therapy will be performed with or without rotational atherectomy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Study: NCT05660057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New computer monitor
Description: The device to be studied is a newly designed computer monitor and will be compared with the standard computer monitor.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: New computer monitor
Description: The device to be studied is a newly designed computer monitor and will be compared with the standard computer monitor.
Study: NCT03637062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pessary
Description: pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
Study: NCT05944497

Intervention type: PROCEDURE
Intervention: Interscalene brachial plexus block
Description: Using a linear ultrasound transducer connected to an ultrasound machine, the compactly arranged brachial plexus is visualized lateral to the pulsating subclavian artery. The transducer is moved cephalad to visualize the 5th to 8th cervical (C5 to C8) nerve roots located between the anterior and middle scalene muscles. Using an in-plane technique, a block needle is inserted close to a nerve root in a lateral-to-medial direction. The needle is moved to place 0.75% ropivacaine around each nerve root. The C8 nerve root is blocked first, and the C5 nerve root is blocked last. After blocking the four cervical nerve roots, ropivacaine is placed in the intermuscular plane between the sternocleidomastoid and scalene muscles to block the supraclavicular nerves. A total of 26 ml of 0.75% ropivacaine is used for the interscalene brachial plexus block (6 ml per nerve root and 2 ml for the supraclavicular nerves).
Study: NCT05661929

Intervention type: OTHER
Intervention: Questionnaire CMQ
Description: The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.
Study: NCT04551482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: 24 IU nasal spray, 4 times per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 IU nasal spray, 4 times per day for 12 weeks
Study: NCT05855980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound closure
Description: Wound is closed or left open to heal secondarily after amputation.
Study: NCT06017895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxepin solution
Description: 2.0 mL doxepin solution (5mg/mL) sprayed to the posterior pharyngeal wall

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2.0 mL placebo sprayed to the posterior pharyngeal wall
Study: NCT05301283

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.
Study: NCT05652517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vein of Marshall ethanol infusion
Description: Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vein of Marshall ethanol infusion
Description: Vein of Marshall ethanol infusion performed during the radiofrequency catheter ablation of persistent or long-standing persistent atrial fibrillation.
Study: NCT06353269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estring Vaginal Product
Description: estradiol vaginal ring, exchanged every 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagifem
Description: vaginal estrogen tablet, used twice per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrace 0.01% Vaginal Cream
Description: vaginal estrogen cream, used twice per week
Study: NCT06719791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Oral administration is given solely for the epilepsy seizure event. Dosage: The dosage is determined based on body surface area (BSA), with 0.5 mg per dose for BSA \<1.2 m², 1 mg per dose for BSA 1.3-2.1 m², and 1.5 mg per dose for BSA \>2.2 m².
Study: NCT06726850

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo arm, participants will consume a placebo matching GenSci1-144 for 12 consecutive weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS1-144
Description: In the GS1-144 arm, participants will receive multiple doses of GS1-144 tablets for 12 consecutive weeks
Study: NCT06750640

Intervention type: DIAGNOSTIC_TEST
Intervention: Infrared thermography
Description: A thermograph (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) was used to record thermal images. The infrared camera was fixed on a tripod 1 m away from the subject to ensure that no shaking movements or vibrations occurred during the recording of thermal images. MDD related acupoints on the inner and outer sides of the limbs were detected. Appropriate body position was selected according to the different parts to be detected. Using the automatic interval saving shooting mode, one thermal picture was taken at 10-s intervals, 3 pictures were taken for each subject.

Intervention type: DIAGNOSTIC_TEST
Intervention: Infrared thermography
Description: A thermograph (NEC InfRec R450, Avio Infrared Technologies Co., Ltd., Tokyo) was used to record thermal images. The infrared camera was fixed on a tripod 1 m away from the subject to ensure that no shaking movements or vibrations occurred during the recording of thermal images. MDD related acupoints on the inner and outer sides of the limbs were detected. Appropriate body position was selected according to the different parts to be detected. Using the automatic interval saving shooting mode, one thermal picture was taken at 10-s intervals, 3 pictures were taken for each subject.
Study: NCT06753825

Intervention type: DEVICE
Intervention: Radiofrequency
Description: radiofrequency treatment

Intervention type: DRUG
Intervention: flunarizine
Description: flunarizine oral treatment
Study: NCT06755983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endorphin massage
Description: For Group 1 (experimental group), patients admitted to the clinic one day before surgery will complete the first two sections of the Patient Diagnosis Form (I. Individual characteristics and II. Health and illness-related data), the Surgical Fear and Anxiety Scale, and the VAS scales after the endorphin massage. The patients will be informed that the endorphin massage will last approximately 20 minutes. According to evidence-based current guidelines, it is stated that the intensity of the patient's pain should be assessed during the preoperative period for pain management planning and goals in the postoperative period. Therefore, patients' pain scores will also be recorded preoperatively using the VAS scale. On the morning of the surgery, before going to the operating room, the endorphin massage will be repeated, and the scales will be applied again. After surgery, patients will have their pain levels measured using the VAS at hours 0, 4, 8, 16, and 24, and the amount of analgesics tak
Study: NCT06756308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Enasidenib 100 mg daily on 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter
Study: NCT06752824

Intervention type: DEVICE
Intervention: ANALGESIA NOCICEPTION INDEX MONITORING
Description: INTRACRANIAL SURGERY
Study: NCT06752785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: CD19/CD22 CAR-T cell therapy
Study: NCT06753344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention app
Description: The app-based intervention, co-designed with the V-YAC, aims to introduce life skills and self-management skills to promote general mental well-being and resilience among Vietnamese youth. With this app, youth users will have a fun and safe space to learn and practice six life skills areas (Problem-solving, Social Media and Well-being, Communication and Interpersonal Skills, Realistic Thinking, Coping with Emotions and Stress, and Goal Setting). Lessons (in the form of short texts) and activities (ex. multiple choice activities, blank worksheets, reflection questions) were adapted from evidence-based interventions developed in other contexts to be culturally appropriate to the Vietnamese youth context. Youth users are free to explore the app at their own pace. Gamification features will also allow youth users to collect points in the app for completing each lesson, activity, or challenge.
Study: NCT06753773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repeated Low-Level Red-Light
Description: All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Low-Level Red-Light
Description: All participants will receive a video guide of the Repeated Low-Level Red-Light device. Eligible subjects will receive daily treatment for 14 days, with each treatment lasting for 3 minutes twice a day, with a minimal interval of 4 hours.
Study: NCT06754891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3906 capsules
Description: TQH3906 is an allosteric inhibitor targeting kinase.
Study: NCT06753214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine-Based Education
Description: Intervention through telemedicine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Care (in control arm)
Description: Sham comparator through telemedicine
Study: NCT06755203

Intervention type: OTHER
Intervention: Operating Room Simulation Training
Description: The intervention involves high-fidelity OR simulations focusing on critical areas of patient safety, including:~Communication Skills: Emphasizing clear communication during surgical procedures.~Stress Management: Training participants to manage stress effectively in high-pressure situations.~Protocol Adherence: Practicing adherence to the WHO Surgical Safety Checklist. Risk Assessment: Identifying and mitigating potential safety risks in simulated scenarios
Study: NCT05281419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone injection
Description: Injecting 40mg triamcinolone into the abscess cavity through the aspiration needle or drainage tube every 1 week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intralesional triamcinolone injection
Description: No intralesional triamcinolone injection